September 19, 2020 Bio/Pharma/CRO Licensing, IP, and Legal Product Launch

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy Final overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours... Read more

September 17, 2020 Licensing, IP, and Legal

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers New integrated analyses from our tumour agnostic Rozlytrek® (entrectinib) clinical development programme Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating GavretoTM(pralsetinib) for the treatment of people with RET-mutant medullary... Read more

September 11, 2020 Licensing, IP, and Legal Product Launch

New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study 97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world data OCREVUS is the first and only treatment approved... Read more

September 10, 2020 Licensing, IP, and Legal

Xylem to participate in RBC Capital Markets Global Industrials Virtual Conference

RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 10, 2020– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its President and CEO, Patrick Decker, and Vice President of Investor Relations, Matt Latino, will participate in a virtual fireside chat hosted by RBC analyst Deane Dray... Read more

September 9, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)

Phase III clinical trial programme initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) Phase IIIb clinical trial programme of higher-dose OCREVUS (ocrelizumab) to evaluate impact on reducing disability progression in RMS and PPMS OCREVUS CHIMES... Read more

September 3, 2020 Licensing, IP, and Legal Product Launch

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020

New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations Initiation of Phase III clinical trial programme for fenebrutinib, an investigational... Read more

August 28, 2020 Chromatography Lab Top-10 Licensing, IP, and Legal Molecular Spectroscopy

Shimadzu and HORIBA to Collaborate on Development and Sales of LC-Raman Analytical and Measuring InstrumentsTowards the Commercialization of Analytical and Measuring Instruments that Combine a High-Performance Liquid Chromatograph and a Raman Spectrometer

08/28/2020 |   Press Release Towards the Commercialization of Analytical and Measuring Instruments that Combine a High-Performance Liquid Chromatograph and a Raman Spectrometer On August 3rd, Shimadzu Corporation (President & CEO: Teruhisa Ueda, hereinafter Shimadzu) and HORIBA, Ltd. (President & COO: Masayuki Adachi, hereinafter HORIBA) concluded a basic agreement to commence collaboration on the development and sales of... Read more

August 27, 2020 Licensing, IP, and Legal Liq. Handling & Robotics

Brooks to Participate in the Citi's 2020 Global Technology Virtual Conference

CHELMSFORD, Mass., Aug. 27, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in Citi’s 2020 Global Technology Virtual Conference on Wednesday, September 9, 2020 which includes a 45-minute webcast beginning at 9:50 a.m. ET.  The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/events. A replay... Read more

August 25, 2020 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System Demonstrated 100 Percent Agreement with Authorized Nasopharyngeal Assays SOUTH SAN FRANCISCO, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight,... Read more

August 19, 2020 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Zymo Research Granted CE IVD Mark for Quick SARS-CoV-2 rRT-PCR Kit

IRVINE, Calif., (Aug. 19, 2020) — Zymo Research announced that it was recently granted the CE IVD Mark for its Quick SARS-CoV-2 rRT-PCR Kit. To obtain this certification the product had to comply with the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. The Quick SARS-CoV-2 rRT-PCR Kit is... Read more